Safety and Efficacy of Immunoadsorption in Heart Transplantation Program

Transplantation Proceedings

Volumn 48, Issue 8, 2016, Pages 2792-2796

  Gazdic, T ^a   Malek, I ^a   Pagacova, L ^a   Slavcev, A ^a   Voska, L ^a   Hegarova, M ^a   Hoskova, L ^a   Kubanek, M ^a   Pirk, J ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHYLPREDNISOLONE; PANEL REACTIVE ANTIBODY; RITUXIMAB; STAPHYLOCOCCUS PROTEIN A; THYMOCYTE ANTIBODY; ANTIBODY;

ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DESENSITIZATION; FEMALE; GRAFT REJECTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; IMMUNOADSORPTION; LIMIT OF DETECTION; MALE; PATIENT SAFETY; PRIORITY JOURNAL; THERAPY EFFECT; ADOLESCENT; DONOR; EVALUATION STUDY; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES; DESENSITIZATION, IMMUNOLOGIC; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSORBENT TECHNIQUES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TISSUE DONORS; YOUNG ADULT;

EID: 84994182297     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2016.06.061     Document Type: Article

References (24)

1. [1] Hammond, E.H., Yowel, R.L., Nunoda, S., et al. Vascular (humoral) rejection in heart transplantation: pathologic observation and clinical implications. J Heart Transplant 8 (1989), 430–443.
2. [2] Michaels, P.J., Espejo, M.L., Kobashigawa, J., et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 22 (2003), 58–69.
3. [3] Berry, G.J., Burke, M.M., Andersen, C., et al. The 2013 International Society for Heart and Lung Transplantation working formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 32 (2013), 1147–1162.
4. [4] Stewart, S., Winters, G.L., Fishbein, M.C., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24 (2005), 1710–1720.
5. [5] Patel, J., Everly, M., Chang, D., et al. Reduction of alloantibodies via proteosome inhibition in cardiac transplantation. J Heart Lung Transplant 30 (2011), 1320–1326.
6. [6] Woodle, E.S., Alloway, R.R., Girnita, A., Proteasome inhibitor treatment of antibody-mediated allograft rejection. Curr Opin Organ Transplant 16 (2011), 434–438.
7. [7] Higgins, R.M., Bevan, D.J., Carey, B.S., et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet, 348, 1996, 1208.
8. [8] Ratkovec, R.M., Hammond, E.J., O'Connell, J.B., et al. Outcome of cardiac transplant recipients with a positive donor-specific crossmatch-preliminary results with plasmapheresis. Transplantation 54 (1992), 651–655.
9. [9] Pisani, B.A., Mullen, G.M., Malinowska, K., et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 18 (1999), 701–706.
10. [10] Bućin, D., Gustafsson, R., Ekmehag, B., et al. Desensitization and heart transplantation of a patient with high levels of donor-reactive anti-human leukocyte antigen antibodies. Transplantation 90 (2010), 1220–1225.
11. [11] Mohacsi, P., Martinelli, M., Banz, Y., Boesch, C., The clinical relevance of antibody-mediated rejection: a new era of heart transplantation. Eur J Cardiothorac Surg 42 (2012), 1047–1049.
12. [12] Kobashigawa, J., Grespo-Leiro, M.G., Ensminger, S.M., et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 30 (2011), 252–259.
13. [13] Gazdic T, Kubanek M, Slimackova E, et al. Pre-transplant anti-HLA antibodies and clinical events after heart transplantation-comparison with conventional predictors. Available from http://www.esot.org/events-education/events/627/programme/2398.
14. [14] Cardella, C.J., Sutton, D.M., Falk, J.A., et al. Effect of intensive plasma exchange on renal transplant rejection and serum cytotoxic antibody. Transplant Proc 10 (1978), 617–619.
15. [15] Böhmig, G.A., Regele, H., Exner, M., et al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J Am Soc Nephrol 12 (2001), 2482–2489.
16. [16] Böhmig, G.A., Wahrmann, M., Regele, H., et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant 7 (2007), 117–121.
17. [17] Grauhan, O., Knosalla, C.H., Ewert, R., et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. J Heart Lung Transplant 20 (2001), 316–321.
18. [18] Kaczmarek, I., Deutsch, M.A., Sadoni, S., et al. Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review. J Heart Lung Transplant 26 (2007), 511–515.
19. [19] Uber, W.E., Self, S.E., Bakel, A.B., Pereira, N.L., Acute antibody-mediated rejection following heart transplantation. Am J Transplant 7 (2007), 2064–2074.
20. [20] Chih, S., Tinckam, K.J., Ross, H.J., A survey of current practice for antibody-mediated rejection in heart transplantation. Am J Transplant 13 (2013), 1069–1074.
21. [21] Gazdic, T., Svobodová, E., Kubánek, M., et al. Bortezomib-containing regimen for primary treatment of early antibody-mediated cardiac allograft rejection: a case report. Progress Transplantation 25 (2015), 1–4.
22. [22] Wu, G.W., Kobashigawa, J.A., Fishbein, M.C., et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant 28 (2009), 417–422.
23. [23] Kfoury, A.G., Hammond, M.E., Snow, G.L., et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J Heart Lung Transplant 28 (2009), 781–784.
24. [24] Plosker, G.L., Figgitt, D.P., Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63 (2003), 803–843.